Hanna Bandos

Contributions to Public Health

• Phase III clinical trials are considered to be a gold standard for demonstrating the effect of an experimental therapy. I am a Senior Biostatistician and the Lead for the Statistics Division, NRG Oncology SDMC, Pittsburgh. In this role, I have been a lead statistician for a number of clinical trials evaluating therapies for prevention and treatment of breast and colorectal cancer. My current primary research interests include statistical aspects of design, implementation and analysis of clinical trials
  • Mamounas EP, Bandos H, Rastogi P, et al. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023;115(11):1302-1309. PMID: 37184928
  • Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2019;20:88-99. PMID: 30509771
• Prevention of late recurrences in patients with hormone receptor-positive breast cancer is of great interest to researchers as it is known for its potential to recur many years after initial treatment. Therefore, it is critical to accelerate biomarker driven research to identify optimal duration of therapy for these patients. I have collaborated on multiple correlative science projects on biosignatures to predict treatment benefit and late recurrence risk
  • Rastogi P, Bandos H, Lucas PC, et al. Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. J Clin Oncol, 2024;42(30): 3561-3569. PMID: 39047219
  • Mamounas EP, Bandos H, Rastogi P, et al. Breast Cancer Index and prediction of extended aromatase inhibitor therapy benefit in hormone receptor-postive breast cancer from the NRG Oncology/NSABP B-42 Trial. Clinical Cancer Res. 2024;30(9):1984-1991. PMID: 38376912
• It has been recognized that physicians underreport and underestimate symptom severity compared with patients’ assessments. Patient-reported outcomes (PRO) and quality-of-life (QOL) studies in cancer patients are often in focus of research efforts. I have been serving as the lead QOL statistician for multiple clinical trials investigating PROs and QOL.
  • Bandos H, Torres-Saavedra PA, Culakova E, et al. Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials. J Natl Cancer Inst Monographs, 2025; 68:14-21
  • Ganz PA, Bandos H, Spanic T, et al. Patient-Reported Outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2–negative early breast cancer. J Clin Oncol 2024;42(11):1288-1300. PMID: 38301187